The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity

Journal of Virology

Volumn 83, Issue 17, 2009, Pages 9002-9007

  Provine, Nicholas M ^a   Puryear, Wendy Blay ^b   Wu, Xueling ^c   Overbaugh, Julie ^c   Haigwood, Nancy L ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROVIRUS; PSEUDOTYPING; RNA TRANSLATION; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS NEUTRALIZATION; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODIES, VIRAL; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV FUSION INHIBITORS; HIV-1; HUMANS; VIRION;

EID: 69249216589     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00423-09     Document Type: Article

References (27)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291. (Pubitemid 16013975)
2. Adams, O., and A. Scheid. 2001. Stepwise deletion of the HIV type 1 glycoprotein 41 N terminus leads to an increasing export of microvesicles containing uncleaved Env glycoprotein. AIDS Res. Hum. Retrovir. 17:1345-1356.
3. Baba, M., O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, Y. Iizawa, M. Shiraishi, Y. Aramaki, K. Okonogi, Y. Ogawa, K. Meguro, and M. Fujino. 1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96:5698-5703.
4. Blay, W. M., T. Kasprzyk, L. Misher, B. A. Richardson, and N. L. Haigwood. 2007. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. J. Virol. 81:13037-13049.
5. Brown, B. K., J. M. Darden, S. Tovanabutra, T. Oblander, J. Frost, E. Sanders-Buell, M. S. de Souza, D. L. Birx, F. E. McCutchan, and V. R. Polonis. 2005. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J. Virol. 79:6089-6101.
6. Chapman, B. S., R. M. Thayer, K. A. Vincent, and N. L. Haigwood. 1991. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19:3979-3986.
7. Chertova, E., J. W. Bess, Jr., B. J. Crise, I. R. Sowder, T. M. Schaden, J. M. Hilburn, J. A. Hoxie, R. E. Benveniste, J. D. Lifson, L. E. Henderson, and L. O. Arthur. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325. (Pubitemid 34517882)
8. Fenyö, E., A. Heath, S. Dispinseri, H. Holmes, P. Lusso, S. Zolla-Pazner, H. Donners, L. Heyndrickx, J. Alcami, V. Bongertz, C. Jassoy, M. Malnati, D. Montefiori, C. Moog, L. Morris, S. Osmanov, V. Polonis, Q. Sattentau, H. Schuitemaker, R. Sutthent, T. Wrin, G. Scarlatti, and D. Unutmaz. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 4:e4505.
9. Freed, E. O., D. J. Myers, and R. Risser. 1989. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J. Virol. 63:4670-4675. (Pubitemid 19257842)
10. Furuta, R. A., C. T. Wild, Y. Weng, and C. D. Weiss. 1998. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:276-279.
11. Herrera, C., P. J. Klasse, E. Michael, S. Kake, K. Barnes, C. W. Kibler, L. Campbell-Gardener, Z. Si, J. Sodroski, J. P. Moore, and S. Beddows. 2005. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 338:154-172. (Pubitemid 40835934)
12. Heyndrickx, L., T. Vermoesen, K. Vereecken, J. Kurth, S. Coppens, L. Aerts, A. Ohagen, Y. Van Herrewege, P. Lewi, and G. Vanham. 2008. Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays. J. Virol. Methods 148:166-173.
13. Li, M., J. F. Salazar-Gonzalez, C. A. Derdeyn, L. Morris, C. Williamson, J. E. Robinson, J. M. Decker, Y. Li, M. G. Salazar, V. R. Polonis, K. Mlisana, S. A. Karim, K. Hong, K. M. Greene, M. Bilska, J. Zhou, S. Allen, E. Chomba, J. Mulenga, C. Vwalika, F. Gao, M. Zhang, B. T. M. Korber, E. Hunter, B. H. Hahn, and D. C. Montefiori. 2006. Genetic and neutralization properties of acute and early subtype C human immunodeficiency virus type 1 molecular env clones from heterosexually acquired infections in southern Africa. J. Virol. 80:11776-11790.
14. Long, E. M., S. M. Rainwater, L. Lavreys, K. Mandaliya, and J. Overbaugh. 2002. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retrovir. 18:567-576.
15. Louder, M. K., A. Sambor, E. Chertova, T. Hunte, S. Barrett, F. Ojong, E. Sanders-Buell, S. Zolla-Pazner, F. E. McCutchan, J. D. Roser, D. Gabuzda, J. D. Lifson, and J. R. Mascola. 2005. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339:226-238.
16. Mascola, J. R., P. D'Souza, P. Gilbert, B. H. Hahn, N. L. Haigwood, L. Morris, C. J. Petropoulos, V. R. Polonis, M. Sarzotti, and D. C. Montefiori. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79:10103-10107.
17. McCune, J. M., L. B. Rabin, M. B. Feinberg, M. Lieberman, J. C. Kosek, G. R. Reyes, and I. L. Weissman. 1988. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53:55-67. (Pubitemid 18104049)
18. Moore, J. P., and D. R. Burton. 2004. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat. Med. 10:769-771.
19. Pancera, M., and R. Wyatt. 2005. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332:145-156. (Pubitemid 40127236)
20. Polonis, V. R., B. K. Brown, A. Rosa Borges, S. Zolla-Pazner, D. S. Dimitrov, M. Y. Zhang, S. W. Barnett, R. M. Ruprecht, G. Scarlatti, E. M. Fenyo, D. C. Montefiori, F. E. McCutchan, and N. L. Michael. 2008. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375: 315-320.
21. Poss, M., and J. Overbaugh. 1999. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J. Virol. 73:5255-5264. (Pubitemid 29274806)
22. Rainwater, S. M., X. Wu, R. Nduati, R. Nedellec, D. Mosier, G. John-Stewart, D. Mbori-Ngacha, and J. Overbaugh. 2007. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr. HIV Res. 5:189-197.
23. Reynard, F., A. Fatmi, B. Verrier, and F. Bedin. 2004. HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. Virology 324:90-102. (Pubitemid 38737403)
24. Roben, P., J. P. Moore, M. Thali, J. Sodroski, C. F. Barbas III, and D. R. Burton. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828. (Pubitemid 24226546)
25. Schutz-Geschwender, A., Y. Zhang, T. Holt, D. McDermitt, and D. M. Olive. 2004. Quantitative, two-color Western blot detection with infrared fluorescence. LI-COR Biosciences, Lincoln, NE. http://www.licor.com/bio/PDF /IRquant.pdf.
26. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 17:1757-1765.
27. Wu, X., A. B. Parast, B. A. Richardson, R. Nduati, G. John-Stewart, D. Mbori-Ngacha, S. M. Rainwater, and J. Overbaugh. 2006. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80:835-844. (Pubitemid 43062895)